Second-line sunitinib for Chinese patients with advanced gastrointestinal stromal tumor: 37.5 mg schedule outperformed 50 mg schedule in adherence and prognosis

BACKGROUND: Sunitinib is widely accepted as a second-line treatment for advanced gastrointestinal stromal tumor (GIST). This study aimed to evaluate patients’ adherence to sunitinib treatment and optimize the dosing schedule for Chinese patients. METHODS: The present study analyzed medical data of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chenli, Zhang, Chen, Zhang, Tianyu, Liu, Hua, Zhong, Jie, Wang, Zhengting, Wang, Liying, Hong, Liwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798138/
https://www.ncbi.nlm.nih.gov/pubmed/35116627
http://dx.doi.org/10.21037/tcr-21-613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798138/
https://www.ncbi.nlm.nih.gov/pubmed/35116627
http://dx.doi.org/10.21037/tcr-21-613

Ejemplares similares